@article{645a1470bbd448318cb42b4186505227,
title = "Developing a pro-regenerative biomaterial scaffold microenvironment requires T helper 2 cells",
abstract = "Immune-mediated tissue regeneration driven by a biomaterial scaffold is emerging as an innovative regenerative strategy to repair damaged tissues. We investigated how biomaterial scaffolds shape the immune microenvironment in traumatic muscle wounds to improve tissue regeneration. The scaffolds induced a pro-regenerative response, characterized by an mTOR/Rictor-dependent T helper 2 pathway that guides interleukin-4-dependent macrophage polarization, which is critical for functional muscle recovery. Manipulating the adaptive immune system using biomaterials engineering may support the development of therapies that promote both systemic and local pro-regenerative immune responses, ultimately stimulating tissue repair.",
author = "Kaitlyn Sadtler and Kenneth Estrellas and Allen, {Brian W.} and Matthew Wolf and Hongni Fan and Tam, {Ada J.} and Patel, {Chirag H.} and Luber, {Brandon S.} and Hao Wang and Wagner, {Kathryn R.} and Powell, {Jonathan D.} and Franck Housseau and Pardoll, {Drew M.} and Elisseeff, {Jennifer H.}",
note = "Funding Information: The authors acknowledge the Sidney Kimmel Comprehensive Cancer Center Flow Cytometry Research Core and L. Blosser for their help on flow cytometric studies; A. Anderson for assistance with adipogenesis studies; S. Sommerfeld and X. Wang for assistance with the clinical product testing; A. Rittenbach for assistance with computed tomography imaging; M. de Palma for generous donation of the iBMM macrophage cell line; M. Swartz and the Swartz lab for assistance in the pilot studies and J.H.E. sabbatical hosting; A. Ewald for helpful discussions; and J. Schneck for critical review. The data presented in this manuscript are tabulated in the main paper and in the supplementary materials. K.S., F.H., D.P., and J.H.E. are inventors on provisional patent application no. 48317-502P01US, filed by Johns Hopkins University (JHU) related to regenerative immunology. J.H.E. holds equity in Aegeria Soft Tissue, a company that has licensed JHU intellectual property not directly related to the materials used in this study but similar enough that it may benefit from the results. The conflict is being managed by the Johns Hopkins Office of Policy Coordination. This work was funded by the Maryland Stem Cell Research Fund (MSCRF), grant 113345; the Armed Forces Institute for Regenerative Medicine; and U.S. Department of Defense grant W81XWH-11-2-0022 (awarded to J.H.E.) and the Jules Stein Professorship from the Research to Prevent Blindness Foundation. M.T.W. was supported by a postdoctoral fellowship from the Hartwell Foundation. D.M.P., J.D.P., B.S.L. and H.W. were supported by Cancer Center Core grant P30CA006973. J.D.P. was supported by a grant from the National Institutes of Health, R01AI077610. J.D.P, J.H.E., and D.M.P acknowledge support from the Bloomberg-Kimmel Institute for Cancer Immunotherapy. Publisher Copyright: {\textcopyright} 2016, American Association for the Advancement of Science. All rights reserved.",
year = "2016",
month = apr,
day = "15",
doi = "10.1126/science.aad9272",
language = "English (US)",
volume = "352",
pages = "366--370",
journal = "Science",
issn = "0036-8075",
publisher = "American Association for the Advancement of Science",
number = "6283",
}